“The gene therapy market is projected to grow at a CAGR of 32% in the first half of the forecast period” says new Visiongain report

06 March 2020
Pharma

Visiongain has launched a new pharma report Gene Therapy R&D and Revenue Forecasts 2020-2030: Retroviruses, Lentiviruses, Adenoviruses, Adeno Associated Virus, Herpes Simplex Virus, Poxvirus, Vaccinia Virus, Naked/Plasmid Vectors, Gene Gun, Electroporation, Lipofection, Cancer, Rare Diseases, Cardiovascular Disorders, Ophthalmologic Conditions, Infectious Disease, Neurological Disorders, Diabetes Mellitus.

The gene therapy market is in early stages of its development, this new Visiongain report analyses the emerging gene therapy market, a field holding great technological and commercial potential. Gene therapy is no longer a treatment solely for rare diseases but has expanded its targets and can now be applied to cancer, cardiovascular diseases, diabetes and more. We have already seen gene therapies launched in recent years and are likely to see upcoming launches due to rapid advancement and the number of clinical trials in this field. Gene therapy has seen many advances in recent years, particularly with vector technology, with AAV and lentiviral vectors showing much potential.

The lead analyst of the report commented "The growth of the overall gene therapy market will be primarily driven by growth in the cardiovascular and rare diseases sector. Clinical trials so far have demonstrated favourable results in a broad range of indications with treatments predicted to launch in the next few years for the cardiovascular disease, rare disease, and cancer submarkets. The market still faces substantial challenges related to ethics, pricing and scalability. Companies looking to market their products optimally should also be developing companion diagnostics for predictive biomarker testing, to market alongside their gene therapies. These companies will also need to agree on creating reimbursements models that will convince health care providers to invest in these novel therapies."

Leading companies featured in the report include UniQure, Biogen, Bluebird Bio, Spark Therapeutics, Applied Genetics Technologies Corporation, Oxford Biomedica, GenSight Biologics and other leading companies currently developing gene therapies. Leading Big Pharma Companies mentioned in this report include Pfizer, Novartis & GSK.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Clinical Trial Supplies Market Report 2021-2031

Deviating from protocols raises the danger of missing or delaying data collection from current investigations. This highlights the growing importance of digital medicine, which is being aided by advancements in cloud, mobile, and IoT technology.

11 October 2021

Read

Visiongain Publishes Drug Discovery Informatics Market Report 2021-2031

High performance HPC and supercomputing technology have evolved substantially in China in the last decades, leading to extraordinary accomplishments. HPC-based and combined pharmaceutical chemical and computational biology computational discovery and design has become a significant technique in drug research and development and is sponsored financially by the Chinese government.

07 October 2021

Read

Visiongain Publishes Pharma Wholesale and Distribution Market Report 2021-2031

Many health-care organizations are seeing organic growth at levels that their supply networks were never designed to handle. Others are frantically attempting to integrate diverse technology and procedures as part of a consolidation effort.

06 October 2021

Read

Visiongain Publishes Meningococcal Vaccines Market Report 2021-2031

Rise in prevalence of meningitis, increasing initiatives by government and regulatory authorities coupled strong funding support from non-profit organizations is expected to drive the global meningococcal vaccines market

05 October 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever